ZA968334B - Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins - Google Patents

Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins

Info

Publication number
ZA968334B
ZA968334B ZA968334A ZA968334A ZA968334B ZA 968334 B ZA968334 B ZA 968334B ZA 968334 A ZA968334 A ZA 968334A ZA 968334 A ZA968334 A ZA 968334A ZA 968334 B ZA968334 B ZA 968334B
Authority
ZA
South Africa
Prior art keywords
proteins
inhibiting
domain
binding
methods
Prior art date
Application number
ZA968334A
Inventor
Elizabeth A Lunney
Mark Stephen Plummer
Alan Robert Saltiel
Aurash Shahripour
Charles John Stankovic
Kimberley Suzanne Para
Josyula Venkata Nagendr Prasad
Tomi Sawyer
Juswinder Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA968334B publication Critical patent/ZA968334B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3834—Aromatic acids (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
ZA968334A 1995-10-04 1996-10-03 Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins ZA968334B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US495495P 1995-10-04 1995-10-04

Publications (1)

Publication Number Publication Date
ZA968334B true ZA968334B (en) 1997-05-13

Family

ID=21713373

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968334A ZA968334B (en) 1995-10-04 1996-10-03 Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins

Country Status (3)

Country Link
AU (1) AU7392696A (en)
WO (1) WO1997012903A1 (en)
ZA (1) ZA968334B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207397B1 (en) 1996-04-18 2001-03-27 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
WO1999024442A1 (en) * 1997-11-12 1999-05-20 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
ATE388139T1 (en) * 1997-12-18 2008-03-15 Boehringer Ingelheim Pharma PYRIDONE AS AN INHIBITOR OF THE SH2 DOMAIN OF THE SRC FAMILY
US6156784A (en) * 1997-12-18 2000-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as phosphotyrosine mimics
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
WO1999047529A1 (en) * 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
JP2002529444A (en) 1998-11-12 2002-09-10 アリアド・ファーマシューティカルズ・インコーポレイテッド Bicyclic signaling inhibitors, compositions containing them and uses thereof
CA2855415A1 (en) 1999-03-23 2000-09-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
FR2793796A1 (en) * 1999-04-14 2000-11-24 Hoechst Marion Roussel Inc Imidazole derivatives having Src SH2 receptor antagonist activity for the prevention and treatment of osteoporosis, auto-immune diseases, proliferative diseases, cancers, allergies and other disorders
FR2796381A1 (en) * 1999-07-12 2001-01-19 Hoechst Marion Roussel Inc Thiazepin and caprolactam bicyclic derivatives, useful in the treatment of e.g. osteoporosis and other bone disorders, infections, allergies or cancers
EP1268775B1 (en) * 2000-04-05 2008-11-19 Oscient Pharmaceuticals Corporation The high bone mass gene of 11q13.3
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
AU2001285133A1 (en) * 2000-08-22 2002-03-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services SH2 domain binding inhibitors
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
AU2002316095A1 (en) 2001-05-11 2002-11-25 Genome Therapeutics Corporation Hbm variants that modulate bone mass and lipid levels
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
WO2005050206A2 (en) * 2003-09-17 2005-06-02 Molecular Probes, Inc. Competitive immunoassay
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
AU2014262621B2 (en) * 2013-05-08 2018-03-01 Baylor College Of Medicine STAT6 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU606808B2 (en) * 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
ATE114661T1 (en) * 1990-04-02 1994-12-15 Pfizer BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS.

Also Published As

Publication number Publication date
WO1997012903A1 (en) 1997-04-10
AU7392696A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
ZA968334B (en) Compounds compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
EP0871444A4 (en) 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
AU4915796A (en) Inhibitors of prenyl transferases
PL324819A1 (en) Derivatives of 4-mercaptopyrrolidine as inhibitors of farnesil transferase
PL322584A1 (en) Inhibitors of proteinous kinase c
PL326754A1 (en) Inhibitors of proteinous kinase c
EP0859771A4 (en) Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL130913A0 (en) Methods and compositions for detectin or quantification of nucleic acid species
AU5922096A (en) Methods and compositions for inhibiting 5alpha-reductase act ivity
PL336990A1 (en) 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
AU2872795A (en) Inhibition of platelet binding
AU5211796A (en) Biocidal compositions comprising mixtures of halopropynyl compounds and sulfur containing triazines
IL123095A0 (en) Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers
AU7529096A (en) Substituted aryl pyrroles, compositions containing such compounds and methods of use
GB9508791D0 (en) Compositions of matter
AU1075099A (en) Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
PL319163A1 (en) Inhibitors of 5 alpha-reductase
AU4479096A (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
PL321870A1 (en) Novel application of compositions containing the mother of pearl
GB9405229D0 (en) Compositions of matter
IL129177A0 (en) Methods and compositions for lipidization of hydrophilic molecules
EP0835104A4 (en) Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
AU7377298A (en) Methods and compositions for use of (iso)eugenol methyltransferase
AU7161096A (en) Compositions and methods for inhibiting the binding of pecam